| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4736 | Sirt1-i5 | Novel SIRT1 Inhibitor, showing potent effect on prostate cancer cell line |
|
| DCC4737 | Sirt1-in-4bb | Novel SIRT1 inhibitor, inducing apoptosis in HCT116 human colon carcinoma cells partially by activating p53 |
|
| DCC4738 | Sirt2-in-6f | Potent and selective inhibitor of SIRT2 |
|
| DCC4739 | Sirt3 Inhibitor P6 | Novel selective SIRT3 inhibitor, exhibiting SIRT3 inhibitory selectivity with IC50 value of 7.2 µM over SIRT1 (32.6 µM) and SIRT2 (33.5 µM), showing potent inhibitory activity against a group of MLLr leukemic cell lines |
|
| DCC4740 | Sir-tz | Novel in situ tetrazine ligation reactive silicon-rhodamine dye |
|
| DCC4741 | Sitafloxacin | Potent broad spectrm fluoroquinolone antibiotic |
|
| DCC4742 | Sitafloxacin Monohydrate | Fluoroquinolone antibiotic, acting as antibacterial, antineoplastic, anti-Infective agents, Inhibiting DNA-gyrase and topoisomerase |
|
| DCC4743 | Si-w052 | Novel inhibitor of lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α and interleukin (IL)-6 on microglia, exhibiting anti-inflammatory activity through ER-stress-mediated autophagy, significantly inducing the conversion ratio of LC3 II/I and |
|
| DCC4744 | Sj1008066 | Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interactionm being cell permeable and having improved activity in the TR-FRET assay (IC50 0.13 µM) |
|
| DCC4745 | Sj3366 | Unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), also inhibiting HIV-2 |
|
| DCC4746 | Sj521054 | Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interaction (IC50 0.40 μM) |
|
| DCC4747 | Sj572710 | Novel Inhibitor of the Disordered Protein, p27(Kip1) |
|
| DCC4748 | Sj-bis | Novel selective MDMX antagonist |
|
| DCC4749 | Sjf-0628 | Novel BRAF-targeting PROTAC, inducing efficient and potent degradation of mutant BRAF but sparing BRAFWT, inhibiting cell growth in mutant-BRAF driven cancer cells |
|
| DCC4750 | Sjf-1521 | Novel selective EGFR degrader |
|
| DCC4751 | Sjf-1528 | Novel potent EGFR degrader, being capable of penetrating the cell membrane, also degrading an exon-20 insertion mutant form of EGFR (ASV duplication) |
|
| DCC4752 | Sjg-136 | Novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity |
|
| DCC4753 | Sjp-l-5 | Novel inhibitor of HIV-1 infection by blocking viral DNA nuclear entry |
|
| DCC4754 | Sk-575 | Highly potent and efficacious proteolysis targeting chimera (PROTAC) degrader of PARP1 for treating cancers, potently inhibiting the growth of cancer cells bearing BRCA1/2 mutations and inducing potent and specific degradation of PARP1 in various human ca |
|
| DCC4755 | Skf64346 Hydrochloride | Inhibitor of Aβ self-aggregation |
|
| DCC4756 | Skf-80723 Hydrobromide | Dopamine D1 receptor agonist |
|
| DCC4757 | Skf-99101h | Selective, brain penetrant 5-HT(1B/D) receptor agonist |
|
| DCC4758 | Ski-349 | Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization |
|
| DCC4759 | Ski-417616 | Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV) |
|
| DCC4760 | S-kkwk | Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin |
|
| DCC4761 | sklb023 | Novel inhibitor of NF |
|
| DCC4762 | Sklb028 | Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin |
|
| DCC4763 | Sklb050 | Biological Active Reagents |
|
| DCC4764 | Sklb-163 | Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK |
|
| DCC4765 | Sklb-329 | Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase |
|
